{"schema_version":"secwatch.filing_event.v1","accession":"0000805928-26-000091","form_type":"8-K","ticker":"AXGN","cik":"0000805928","company_name":"Axogen, Inc.","filed_at":"2026-07-29T11:11:02+00:00","discovered_at":"2026-07-29T11:15:00.515688+00:00","generated_at":"2026-07-29T11:15:13.441316+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Axogen Q2 revenue $69.7M (+23% YoY), raises FY2026 guidance to at least $279M (24% growth)","bullets":["Revenue $69.7M, up 23.1% YoY; net loss $1.5M ($0.03/sh) vs net income $0.6M ($0.01/sh) in Q2 2025.","Adjusted net income $7.3M ($0.12/sh) vs $5.7M ($0.12/sh) YoY; adjusted EBITDA $8.4M vs $9.3M.","Raises FY2026 revenue guidance to at least $279M (24% growth); gross margin guidance at least 73%; expects positive free cash flow.","Gross margin 72.7% vs 74.2% due to product mix shift from >50% Breast growth.","Cash and investments $113.4M, up $9.8M from Q1 2026; minority stake in Trace Biosciences."],"urls":{"canonical":"https://secwatch.observer/filing/0000805928-26-000091","json":"https://secwatch.observer/filing/0000805928-26-000091.json","markdown":"https://secwatch.observer/filing/0000805928-26-000091.md","text":"https://secwatch.observer/filing/0000805928-26-000091.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/805928/000080592826000091/0000805928-26-000091-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/805928/000080592826000091/axgn-20260729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-29T11:15:13.441316+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}